Association of PAK4 expression with overall survival in patients with non-small cell lung cancer (NSCLC).

Hirva Mamdani(Wayne State University), Asfar S. Azmi(The Barbara Ann Karmanos Cancer Institute), B. Halmos(Albert Einstein College of Medicine), Husain Yar Khan(Wayne State University), W. Michael Korn(Itasca Community College), Stephen V. Liu(Georgetown University), Erin E. Morgan(Caris Life Sciences (United States)), Hina Khan(Albert Einstein College of Medicine), Sharon Wu(Caris Life Sciences (United States)), C. Patrick(Penn State Milton S. Hershey Medical Center), Sonam Puri(University of Utah), Gilberto Lopes(University of Miami), Jorge J. Nieva(University of Southern California), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Hossein Borghaei(Fox Chase Cancer Center), Chadi Nabhan(University of Chicago), Luis E. Raez(Florida International University)
Journal of Clinical Oncology
June 1, 2022
10.1200/jco.2022.40.16_suppl.e21149
Cited by 2

Related Papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k